Trends and disparities in polycythemia vera–related mortality in the United States from 1999 to 2020.

e22557 Background: Polycythemia Vera (PV) is a rare JAK2-mutated myeloproliferative neoplasm with a 5-year survival rate of approximately 79.5%. Patients are at an increased risk of secondary malignancies, leukemic transformation, and fatal thromboembolic events, all of which can significantly impact long-term survival. Analyzing trends in PV-related deaths is crucial for understanding these risks and improving patient outcomes. Methods: Crude mortality rates (CMRs) and age-adjusted mortality rates (AAMRs) per 100,000 population from 1999 to 2020 were extracted from the CDC Wide-Ranging Online Data for Epidemiological Research (WONDER) database using ICD-10 code D45. AAMRs were stratified by year, gender, race, age groups, place of death, and region. Annual percentage change (APC) in AAMR was calculated using Joinpoint regression (V 5.2.0, National Cancer Institute). Results: From 1999 to 2020, 21,270 deaths related to PV were reported. The AAMR declined from 0.4 in 1999 to 0.22 in 2015 (APC = -3.75%, 95% CI: -4.07% to -3.42%, p < 0.001). However, after 2015, the trend reversed, with the AAMR rising to 0.28 in 2020 (APC = 3.95%, 95% CI: 1.55% to 6.40%, p = 0.028). Throughout the study period, men had higher AAMR values (overall AAMR = 0.34) than women (overall AAMR = 0.25). Non-Hispanic White individuals had the highest overall AAMR (0.31), with a decline from 1999 to 2015 (APC = -3.74%, p < 0.001) and an increase from 2015 to 2020 (APC = 3.94%, p = 0.012). Age-related increases in mortality were evident, with the highest AAMR seen in individuals over 85 years (AAMR = 5.6). Regionally, the Midwest had the highest AAMR (0.34), followed by the West (0.32), Northeast (0.29), and South (0.23). In rural areas, the overall AAMR was higher (0.32) compared to urban areas (0.29). Urban areas saw a decline in AAMR from 1999 to 2015 (APC = -3.96%, p < 0.001), followed by an increase from 2015 to 2020 (APC = 3.86%, p = 0.017). Rural areas experienced a steady decline from 1999 to 2017 (APC = -2.82%, p < 0.001), followed by a sharp increase from 2017 to 2020 (APC = 11.38%, p = 0.003).Regarding the location of death, 41% occurred in medical facilities, 32.7% at home, 3.2% in hospices, 18.9% in nursing homes, and 4.1% in other or unknown locations. Conclusions: From 1999 to 2015, PV-related mortality declined but began to rise after 2015, continuing through 2020. Disparities in mortality were observed across gender, age, race, region, and urbanization. These findings emphasize the need for targeted interventions, tailored treatments, and further research to address the increased mortality risk associated with PV.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-05-28
DOI
https://doi.org/10.1200/jco.2025.43.16_suppl.e22557
Primary Topic
Myeloproliferative Neoplasms: Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Trends and disparities in polycythemia vera–related mortality in the United States from 1999 to 2020.

Shammas Bajwa, Ahmad Nawaz, Zaheer Qureshi, Sufyan Shahid et al.
Journal of Clinical Oncology
Myeloproliferative Neoplasms: Diagnosis and Treatment
article

Trends and disparities in polycythemia vera–related mortality in the United States from 1999 to 2020.

Shammas Bajwa, Ahmad Nawaz, Zaheer Qureshi, Sufyan Shahid, Mahnoor Fatima, Maria Qadri, Ayesha Siddiqua, Faiza Fatima, Ali Muhammad, Minhal Chaudhry, Ahmed Raza, Iqra Shahid, Umaima Cheema, Filza Waqar
article en

Abstract

e22557 Background: Polycythemia Vera (PV) is a rare JAK2-mutated myeloproliferative neoplasm with a 5-year survival rate of approximately 79.5%. Patients are at an increased risk of secondary malignancies, leukemic transformation, and fatal thromboembolic events, all of which can significantly impact long-term survival. Analyzing trends in PV-related deaths is crucial for understanding these risks and improving patient outcomes. Methods: Crude mortality rates (CMRs) and age-adjusted mortality rates (AAMRs) per 100,000 population from 1999 to 2020 were extracted from the CDC Wide-Ranging Online Data for Epidemiological Research (WONDER) database using ICD-10 code D45. AAMRs were stratified by year, gender, race, age groups, place of death, and region. Annual percentage change (APC) in AAMR was calculated using Joinpoint regression (V 5.2.0, National Cancer Institute). Results: From 1999 to 2020, 21,270 deaths related to PV were reported. The AAMR declined from 0.4 in 1999 to 0.22 in 2015 (APC = -3.75%, 95% CI: -4.07% to -3.42%, p < 0.001). However, after 2015, the trend reversed, with the AAMR rising to 0.28 in 2020 (APC = 3.95%, 95% CI: 1.55% to 6.40%, p = 0.028). Throughout the study period, men had higher AAMR values (overall AAMR = 0.34) than women (overall AAMR = 0.25). Non-Hispanic White individuals had the highest overall AAMR (0.31), with a decline from 1999 to 2015 (APC = -3.74%, p < 0.001) and an increase from 2015 to 2020 (APC = 3.94%, p = 0.012). Age-related increases in mortality were evident, with the highest AAMR seen in individuals over 85 years (AAMR = 5.6). Regionally, the Midwest had the highest AAMR (0.34), followed by the West (0.32), Northeast (0.29), and South (0.23). In rural areas, the overall AAMR was higher (0.32) compared to urban areas (0.29). Urban areas saw a decline in AAMR from 1999 to 2015 (APC = -3.96%, p < 0.001), followed by an increase from 2015 to 2020 (APC = 3.86%, p = 0.017). Rural areas experienced a steady decline from 1999 to 2017 (APC = -2.82%, p < 0.001), followed by a sharp increase from 2017 to 2020 (APC = 11.38%, p = 0.003).Regarding the location of death, 41% occurred in medical facilities, 32.7% at home, 3.2% in hospices, 18.9% in nursing homes, and 4.1% in other or unknown locations. Conclusions: From 1999 to 2015, PV-related mortality declined but began to rise after 2015, continuing through 2020. Disparities in mortality were observed across gender, age, race, region, and urbanization. These findings emphasize the need for targeted interventions, tailored treatments, and further research to address the increased mortality risk associated with PV.

Journal of Clinical OncologyVol. 43(16_suppl)
Services Institute of Medical Sciences (PK), King Edward Medical University (PK), AdventHealth Orlando (US), Jinnah Sindh Medical University (PK), Quinnipiac University (US)
Openalex Percentile: Top 83%
Myeloproliferative Neoplasms: Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.